BBOT
BridgeBio Oncology Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$643.26M
P/E Ratio
—
EPS
$-1.92
Beta
0.22
52W High
$14.87
52W Low
$7.60
50-Day MA
$8.69
200-Day MA
$10.68
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-168.56M |
| Operating Margin | 0.00% |
| Return on Equity | -62.20% |
| Return on Assets | -37.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.65 |
| Price-to-Book | 1.84 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $80.11M |
| Float | $35.75M |
| % Insiders | 27.20% |
| % Institutions | 68.86% |
Historical Volatility
HV 10-Day
56.94%
HV 20-Day
52.93%
HV 30-Day
54.74%
HV 60-Day
56.77%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($25.11 target)
3
Strong Buy7
BuyMore HEALTHCARE Stocks
Data last updated: 6/6/2026